Descovy

FTC/TAF emtricitabine/tenofovir alafenamide

Recommended as a component of initial regimen for most people
Nucleoside "Nuke"

Standard Dose

One tablet once daily, without regard to food. Tablet contains 200 mg emtricitabine and 25 mg tenofovir alafenamide. For adults and children weighing at least 55 pounds (25 kg), or 77 pounds (35 kg) if taking Descovy with a boosted protease inhibitor. Crushing or splitting tablets has not been studied and is not recommended; TAF is soluble in water, but has a bitter and burnt aromatic flavor profile. Must be taken in combination with another antiretroviral(s) which does not contain the medications in this drug combination.

Take a missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Descovy should not be used if CrCl is less than 30 mL/min, but can be used if CrCl is less than 15 mL/min if you are on dialysis. Descovy was approved for HIV prevention (pre-exposure prophylaxis, or PrEP) in October 2019; see “Descovy for PrEP” page.

See the individual drugs contained in Descovy: Emtriva (but TAF is not available separately for HIV).

See package insert for more complete information on potential side effects and interactions.

Manufacturer

Gilead Sciences, Inc.
gilead.com
descovy.com
(800) GILEAD-5 (445–3235)

AWP

$2,210.74/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments